The global oral solid dosage pharmaceutical formulation market to grow from US$ 493.2 Bn in 2017 to US$ 926.3 Bn by 2027 end. This represents a value CAGR of 6.5% over the forecast period 2017– 2027. Several important factors drive this growth.

This is what says the report prepared by Future Market Insights (IMF) before the summer.

North America the largest market …

North America will remain the largest market for oral-controlled release technology, and the trend is projected to continue throughout the forecast period. North America is expected to be the most lucrative among all regions, with a market attractiveness index of 2.7.

Diminishing share of oral solids in the development pipeline

Growing research on biologics molecules and their dominance in treating oncology conditions are hampering the growth of the oral solid dosage pharmaceutical formulation market. Approximately 50% of the pipeline molecules are biologics and the rest in the form of other dosage forms. Companies are betting heavily on biologics owing to their high returns in terms of value. For instance, in 2016, the top 10 drugs generated around US$ 79 Bn in terms of value; among these, 76.8% were from biologics.